BLOOMFIELD, Conn.--(BUSINESS WIRE)--CIGNA (NYSE:CI) announced today that it has reached an agreement with Merck & Co., Inc. that is unique in the industry. The agreement will benefit CIGNA customers through increased discounts on Merck’s oral anti-diabetes medications Januvia® and Janumet®. These drugs are used in conjunction with diet and exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes, a condition that has reached epidemic proportions in the United States.
